上述研究队列中,在159例接受不同剂量DS-1062的晚期或转移性NSCLC患者中观察到的ORR为21%-25%。在可评价的3种DS-1062用药剂量下,观察到的DCR为67%-80%,中位PFS为4.3个月-8.2个月。年2020ESMO公布的亚组分析表明,在34例驱动基因异常的NSCLC患者中,ORR高达35%。中位随访13.4个月时,中位DOR为9.5个月。即使在接受奥希替尼治疗后,EGFR外显子19缺失和L858R突变患者对DS-1062仍有治疗反应[17]。并且,21年20世界肺癌大会(WCLC)[21]公布了推荐剂量6mg/kg组的ORR高达28%,中位DOR长达10.5个月,40%的患者疾病稳定。 图1. DS-8201和DS-1062正在进行的III期临床试验 DS-8201和DS-1062同属于采用DXd-ADC平台技术的新型ADC药物,具有强效的抗肿瘤活性,系列II/III研究进展正在不断验证其针对多种晚期实体瘤的良好疗效。在人类与恶性肿瘤不断抗争的征程中,DS-8201和DS-1062为代表的ADC药物将化身攻克癌症的有力治疗“武器”,为晚期实体瘤患者创造更多生存希望。 参考文献[1]Indini A, Rijavec E, Grossi F. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. Int J Mol Sci. 2021 Apr 30;22(9):4774.[2]Tamura K, Tsurutani J, Takahashi S, et al.Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: A dose-expansion, phase 1 study. Lancet Oncol. 2019, 20, 816–826.[3] Modi S, Park H, Murthy RK,et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer:Results From a Phase Ib Study. J. Clin. Oncol. 2020, 38, 1887–1896.[4] Modi S, Saura C, Yamashita T,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N. Engl. J. Med. 2020, 382, 610–621.[5]Keam SJ, Trastuzumab Deruxtecan: First Approval. Drugs 2020, 80, 501–508.[6]Modi S, Saura C, Yamashita T, et al., Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7): 610–621.[7] Saura C, Modi S, Ian Krop I,et al.Trastuzumab Deruxtecan (T-DXd)in Patients with HER2-Positive Metastatic Breast Cancer: Updated Survival Results from a Phase 2 Trial (DESTINY-Breast01).2021 ESMO. 279P.[8]Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan (DS-8201) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINYBreast03 study.2021 ESMO.LBA1.[9]Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer : Subgroup analyses from the Randomized Phase 3 DESTINY-Breast03 Study. 2021SABCS.GS3-01.[10]Shitara K, Iwata H, Takahashi S, et al.Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: A dose-expansion, phase 1 study. Lancet Oncol. 2019, 20, 827–836.[11]Shitara K, Bang YJ, Iwasa S, et al.Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N. Engl. J. Med. 2020, 382, 2419–2430.[12] Shitara K, Bang YJ, Iwasa S, et al.Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ)adenocarcinoma: A randomized, phase II.; multicenter, open-label study (DESTINY-Gastric01). J. Clin. Oncol. 2020, 38 (Suppl.abstr 4513).[13]Yamaguchi K, Bang Y, Iwasa S,et al.Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ)adenocarcinoma: Results of the exploratory cohorts in the phase II.; multicenter, open-label DESTINY-Gastric01 study. Ann.Oncol. 2020, 31 (Suppl. 4), S841–S873.[14]Smit EF, Nakagawa K, Nagasaka M, et al.Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. J. Clin. Oncol. 2020, 38 (Suppl. abstr 9504).[15]Siena S, Di Bartolomeo M, Raghav KPS, et al. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. J. Clin. Oncol. 2020, 38 (Suppl. abstr 4000).[16]Seligson JM, Patron AM, Berger MJ, et al. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. Ann Pharmacother. 2021 Jul;55(7):921-931.[17]https://news.cancerconnect.com/lung-cancer/datopotamab-treatment-for-non-small-cell-lung-cancer[18]Okajima D, Yasuda S, Maejima T, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Dec;20(12):2329-2340.[19] Bardia A. Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase 1 trial. Ann Oncol. 2021;32(suppl2):S60-S78. 2021 ESMO BC. Abstract LBA4. doi:10.1016/annonc/annonc508[20]GS1-05 Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study.Presented at: 2021 San Antonio Breast Cancer Symposium; December 7-10, 2021; San Antonio, TX.[21] Edward B Garon et al. TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors. Presented at WCLC 2021.Abstract MA03.02*此文仅用于向医学人士提供科学信息,不代表本平台观点